Oncology & Cancer

Benefit of PSA reduced by loss of quality-adjusted life-years

(HealthDay) -- Although the European Randomized Study of Screening for Prostate Cancer (ERSPC) has reported a 29 percent reduction in prostate-cancer mortality for men who undergo prostate-specific antigen (PSA) screening, ...

Oncology & Cancer

Age a big factor in prostate cancer deaths

Contrary to common belief, men age 75 and older are diagnosed with late-stage and more aggressive prostate cancer and thus die from the disease more often than younger men, according to a University of Rochester analysis ...

Oncology & Cancer

New prostate cancer screening test shows promise for diagnosis

A new prostate screening test developed by AnalizaDx, Inc., a Cleveland-based biotech company, and studied by researchers at the Seidman Cancer Center at University Hospitals (UH) Case Medical Center along with colleagues ...

page 10 from 33